Skip to main content
Face hiding behind the inner workings of a clock

Time Is Hiding Something

In Alzheimer’s disease (AD), biomarker tools can help uncover what’s been hiding under the surface for years1-3

SEE WHAT TIME HIDES

It’s time to act

A growing healthcare crisis

Rising bar graph icon

As the aging population grows, the impact and burden of AD will likely increase too.4

DISCOVER WHY

Timely detection and diagnosis

Brain icon

Timely detection and diagnosis of AD are important because they may enable earlier initiation of informed disease management, earlier opportunities to support cognitive well-being, and earlier consideration of therapeutic options.3,5

LEARN MORE

Early-stage clinical tools

Clinical tools icon

Brief, objective tools can help you better detect the early signs of cognitive impairment.6,7

EXPLORE MORE

Advanced diagnostic tools

Magnifying glass over biomarker icon

Biomarker testing may increase the confidence in your AD diagnosis in patients with cognitive impairment and help inform patient care.8,9

DISCOVER MORE

At Lilly, we are committed to partnering with you to improve the diagnostic journey for patients in the early stages of AD.

Trio of AD Patients Standing Together

References:

  1. Aisen PS, Cummings J, Jack CR Jr, et al. On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimers Res Ther. 2017;9(1):60. doi:10.1186/13195-017-0283-5
  2. Mattsson-Carlgren N, Anderson E, Janelidze S, et al. Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease. Sci Adv. 2020;6(16): eaaz2387. doi:10.1126/sciadv.aaz2387
  3. Porsteinsson AP, Isaacson RS, Knox S, et al. Diagnosis of early Alzheimer’s disease: clinical practice in 2021. J Prev Alzheimers Dis. 2021;8:371-386.
  4. Alzheimer’s Association. 2022 Alzheimer’s disease facts and figures. Alzheimers Dement. 2022;18(4):700-789.
  5. Galvin JE, Aisen P, Langbaum JB, et al. Early stages of Alzheimer’s disease: evolving the care team for optimal patient management. Front Neurol. 2021;11:592302.
  6. Cordell CB, Borson S, Boustani M, et al. Alzheimer’s Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting. Alzheimers Dement. 2013;9(2):141-150.
  7. Borson S, Scanlan JM, Watanabe J, et al. Improving identification of cognitive impairment in primary care. Int J Geriatr Psychiatry. 2006;21(4):349-355.
  8. Andersen E, Casteigne B, Chapman WD, et al. Diagnostic biomarkers in Alzheimer’s disease. Biomark Neuropsychiatry. July 15, 2021. Accessed June 27, 2022. doi:10.1016/j.bionps.2021.100041
  9. Leuzy A, Mattsson-Carlgren N, Palmqvist S, et al. Blood-based biomarkers for Alzheimer’s disease. EMBO Mol Med. 2022;14(1):e14408. doi:10.15252/emmm.202114408